- $1.23m
- -$8.23m
- $0.67m
Brief: Vyant Bio Announces Stockholder Approval Of Plan Of Dissolution
Brief: Vyant Bio Files Form 15 For Voluntary Nasdaq Delisting And SEC Deregistration
Brief: Vyant Bio Announces Filing Of Form 25 For Voluntary Nasdaq Delisting And SEC Deregistration
Brief: Vyant Bio Announces Voluntary Nasdaq Delisting, SEC Deregistration
Vyant Bio Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Vyant Bio Inc - On March 20, Received A Written Notice From Nasdaq Indicating That Co Is Not In Compliance With $1.00 Minimum Bid Price Requirement
U.S. STOCKS ON THE MOVE-Energy index, Church & Dwight, Personalis
Vyant Bio falls on plans to delay clinical studies
Brief: Vyant Bio Inc Says Under Cash Preservation Plan Of Jan 31, Co Sees To Incur About $1.4 Mln For Employee Termination-Related Costs In Q1, Q2 Of 2023
Brief: Vyant Bio Commences Cash Preservation Plan Including Reduction In Force
Brief: Vivopharm PTY Enters Into Share Purchase Agreement
U.S. STOCKS ON THE MOVE-Walgreens, Silvergate, Bed Bath & Beyond
U.S. STOCKS ON THE MOVE-Amazon, Western Digital, Nordstrom
Brief: Vyant Bio Engages Lifesci Capital To Explore Strategic Alternatives
U.S. STOCKS ON THE MOVE-Tesla, Exxon Mobil, Chevron
Brief: Vyant Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement
Vyant Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Vyant Bio Reports Q3 Results And Provides Strategic And Business Highlights
Vyant Bio Inc expected to post a loss of 70 cents a share - Earnings Preview